



A rapid systematic review of breakthrough pain definitions and descriptions

British Journal of Pain
2024, Vol. 18(3) 215–226
© The Author(s) 2023



Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/20494637231208093
journals.sagepub.com/home/bjp



Katie Greenfield¹, Daniel E Scoth¹, Richard Hain² ,
Simon Bailey³, Christine Mott^{4,5}, Dilini Rajapakse⁶,
Emily Harrop^{7,8}, Kate Renton^{9,10}, Anna-Karenia Anderson¹¹,
Bernie Carter¹², Margaret Johnson¹³ and Christina Lioffi^{1,14} 

Abstract

Background: Breakthrough pain is common in life-limiting conditions and at end-of-life. Despite over 30 years of study, there is little consensus regarding the definition and characteristics of breakthrough pain.

Objective: This study aims to update and expand a 2010 systematic review by Haugen and colleagues to identify (1) all definitions of breakthrough pain and (2) all descriptions and classifications of breakthrough pain reported by patients, caregivers, clinicians, and experts.

Design: This rapid systematic review followed the Cochrane Rapid Review Methods Group guidelines. A protocol is published on PROSPERO (CRD42019155583).

Data sources: CINAHL, MEDLINE, PsycINFO, and the Web of Science were searched for breakthrough pain terms from the inception dates of each database to 26th August 2022.

Results: We identified 65 studies that included data on breakthrough pain definitions, descriptions, or classifications from patients ($n = 30$), clinicians ($n = 6$), and experts ($n = 29$), but none with data from caregivers. Most experts proposed that breakthrough pain was a sudden, severe, brief pain occurring in patients with adequately controlled mild-moderate background pain. However, definitions varied and there was no consensus. Pain characteristics were broadly similar across studies though temporal factors varied widely. Experts classified breakthrough pain into nociceptive, neuropathic, visceral, somatic, or mixed types. Patients with breakthrough pain commonly experienced depression, anxiety, and interference with daily life.

¹School of Psychology, University of Southampton, Highfield, UK

²Paediatric Palliative Medicine, Noah's Ark Children's Hospital for Wales, Cardiff, UK

³Sir James Spence Institute, Royal Victoria Infirmary, Newcastle upon Tyne, UK

⁴Acorns Children's Hospice, Birmingham, UK

⁵Birmingham Children's Hospital, Birmingham, UK

⁶Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK

⁷Helen & Douglas House Hospices, Oxford, UK

⁸Oxford University Hospitals NHS Trust, John Radcliffe Hospital, Oxford, UK

⁹University Hospital Southampton NHS Trust, Southampton General Hospital, Southampton, UK

¹⁰Naomi House & Jacksplace, Winchester, UK

¹¹Royal Marsden Hospital, Sutton, UK

¹²Faculty of Health, Social Care and Medicine, Edge Hill University, Ormskirk, UK

¹³Patient & Public Representative, London, UK

¹⁴Psychological Services Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK

Corresponding author:

Christina Lioffi, School of Psychology, University of Southampton, Highfield Campus, Southampton, S017 1BJ, UK.

Email: cliossi@soton.ac.uk

Conclusions: Despite ongoing efforts, there is still no consensus on the definition of breakthrough pain. A compromise is needed on breakthrough pain nomenclature to collect reliable incidence and prevalence data and to inform further refinement of the construct.

Keywords

Breakthrough pain, pain classification, systematic review

Introduction

Adults and children with cancer, life-limiting conditions, and those at end-of-life^{1,2} commonly experience continuous mild-moderate pain (background pain) and acute episodes of more severe pain, known as breakthrough pain. The definition of breakthrough pain varies in the literature, affecting reported prevalence. A systematic review reported pooled prevalence rates of 59.2% in adults with cancer.³ Paediatric breakthrough pain prevalence estimates are limited to a small, retrospective narrative review of medical records⁴ and a study reporting that 15 of 27 hospitalised children with cancer (57%) had experienced breakthrough pain in the previous 24-h.⁵ Yet, anecdotal evidence suggests rates are much higher.^{4,6} Breakthrough pain management is often inadequate,^{5,7} causing significant detrimental effects on wellbeing, quality of life, and functioning.^{8–10} Continuous careful evaluation of a patient's pain is essential for effective breakthrough pain management.¹¹

In 2010, Haugen and colleagues conducted a systematic review of the assessment and classification of cancer breakthrough pain.¹² Although the authors found broad agreement in cancer breakthrough pain definitions, they found no single, broadly accepted breakthrough pain definition, assessment tool, or classification system. Moreover, our recent systematic review found a lack of valid, reliable breakthrough pain assessment tools.^{13,14} Only the Breakthrough Pain Assessment Tool¹⁰ could be recommended for use, but this is a self-report tool only validated to characterise breakthrough pain in adults with cancer.

Our research aims to update and expand Haugen and colleagues' (2010) systematic review to identify breakthrough pain definitions, descriptions, and classifications of all types experienced by patients of all ages and with any medical condition. The current review was undertaken to identify (1) all definitions of breakthrough pain and (2) all descriptions, experiences, and classifications of breakthrough pain reported by patients, caregivers, clinicians, and experts. A great majority of clinicians and researchers, including the authors of this review, maintain the view that the current plethora of breakthrough pain definitions makes communication between professionals and

families difficult, has significant adverse consequences for the clinical management of patients, and undermines reliable incidence and prevalence data collection. By providing a comprehensive and exhaustive summary of definitions of breakthrough pain, we hope this will serve as a small first step towards achieving an eventual consensus in a definition of breakthrough pain.

Methods

This rapid systematic review is part of a large multi-centre study (the BEACON study) aiming to develop a validated paediatric breakthrough pain assessment tool. PRISMA guidelines¹⁵ were followed ([Supplementary File 1](#)) and the Cochrane Rapid Review Methods Group guidelines.¹⁶ A detailed description of the methods, including the full search strategy, is included in our protocol¹⁷ (PROSPERO: CRD42019155583). CINAHL, MEDLINE, PsycINFO, and Web of Science were searched from database inception to 26th August 2022. The reference lists of eligible articles were also screened. A search strategy was developed incorporating search terms in two blocks: 1. 'breakthrough pain' and 2. 'definitions, descriptions, characteristics, experiences, and classifications'.

KG extracted the relevant information into bespoke data extraction templates ([Supplementary File 2](#)). The extracted information was reviewed by DES and CL. The data was first grouped depending on the source (expert, clinician, family caregiver, or patient) to identify differences in breakthrough pain definitions and descriptions. The data was then synthesised descriptively to identify (1) breakthrough pain definitions endorsed by experts and clinicians, and used as inclusion criteria for studies involving patients with breakthrough pain, and (2) the most commonly reported and consistent breakthrough pain descriptors. A bespoke study quality assessment tool was developed for the study ([Table 1](#)). For empirical studies with healthcare professionals, experts, and patients, questions were based on items from the LEGEND Evidence Appraisal of a Single Study (All domains; Expert Opinion) tool¹⁸ from the Cincinnati Children's Hospital Medical Center and the Appraisal tool for Cross-Sectional Studies (AXIS).¹⁹ For DELPHI studies,

Table 1. Quality assessment tool adapted from the LEGEND evidence appraisal of a single study (all domains; expert opinion) tool and the appraisal tool for cross-sectional studies (AXIS).

Empirical studies with patients	1	2	3	4	5	6	7	8	9	10
Bedard, Hawley et al., 2013 ²⁷	Yes	Yes	No	No	NA	Yes	Yes	Yes	Yes	Yes
Bhatnagar, Upadhyay et al., 2010 ²⁸	Yes	Yes	No	Yes	No	Yes	Yes	Yes	Yes	Yes
Caraceni, Martini et al. 2004 ⁶⁰	Yes	Yes	No	No	NA	Yes	Yes	Yes	Yes	Yes
Cascella, Crispo et al., 2021 ⁵⁰	Yes	Yes	No	No	NA	Yes	Yes	Yes	Yes	Yes
Davies, Buchanan et al., 2013 ³⁴	No	No	NA	NA	NA	Yes	Yes	Yes	Yes	Yes
Davies, Zeppetella et al., 2011 ³⁵	No	No	NA	NA	NA	Yes	Yes	Yes	Yes	Yes
Fan, Li et al., 2022 ⁵³	No	No	NA	NA	NA	Yes	Yes	Yes	Yes	Yes
Ferrero, Oset et al., 2019 ³⁷	No	No	NA	NA	NA	Yes	Yes	Yes	Yes	Yes
Fine & Busch 1998 ²¹	Yes	Yes	No	No	NA	Yes	Yes	Yes	Yes	Yes
Hansen, Frost, et al., 2019 ³⁰	Yes	Yes	No	No	NA	Yes	Yes	Yes	Yes	Yes
Gutgsell, Walsh et al., 2003 ⁵⁸	Yes	Yes	No	Yes	No	Yes	Yes	Yes	Yes	Yes
Kang, Koh et al., 2020 ⁵¹	No	NA	NA	NA	NA	Yes	Yes	Yes	Yes	Yes
Katz, Gajria et al., 2017 ⁴⁹	No	NA	NA	NA	NA	Yes	Yes	Yes	Yes	Yes
Lasheen, Walsh et al., 2010 ²⁹	No	NA	NA	NA	NA	Yes	Yes	No	NA	Yes
Liu, Gao et al., 2018 ²⁴	No	Yes	NA	NA	NA	Yes	Yes	Yes	Yes	Yes
Madariaga Muñoz, Villegas Estévez et al., 2018 ²²	Yes	Yes	No	No	NA	Yes	Yes	Yes	Yes	Yes
Mercadante, Adile et al., 2014 ⁵²	No	NA	NA	NA	NA	Yes	Yes	No	DK	Yes
Mercadante, Adile et al., 2013 ³¹	No	NA	NA	NA	NA	Yes	Yes	Yes	Yes	Yes
Mercadante, Maltoni et al., 2021 ⁵⁷	Yes	Yes	No	Yes	No	Yes	Yes	DK	DK	Yes
Narayana, Katz et al., 2015 ⁹	Yes	Yes	No	No	NA	Yes	Yes	Yes	Yes	Yes
O'Hagan, Mercadante et al., 2018 ³²	No	NA	NA	NA	NA	Yes	Yes	Yes	Yes	Yes
Pathmawathi, Beng et al., 2015 ²⁵	Yes	Yes	No	No	NA	Yes	Yes	Yes	Yes	Yes
Pérez-Hernández, Blasco et al., 2019 ³⁶	No	NA	NA	NA	NA	Yes	Yes	Yes	DK	Yes
Petzke, Radbruch et al., 1999 ⁵⁴	No	NA	NA	NA	NA	Yes	Yes	Yes	Yes	Yes
Portenoy, Bruns, et al., 2010 Part 1 ⁵⁵	Yes	Yes	No	Yes	No	Yes	Yes	Yes	Yes	Yes
Portenoy, Bruns, et al., 2010 Part 2 ⁵⁹	Yes	Yes	No	No	NA	Yes	Yes	Yes	Yes	Yes
Portenoy & Hagen, 1989 ⁵⁶	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No	Yes
Portenoy & Hagen, 1990 ³³	Yes	Yes	No	Yes	No	Yes	Yes	Yes	Yes	Yes
Torres, Jiménez et al., 2018 ²³	Yes	Yes	No	Yes	No	Yes	Yes	No	DK	Yes
Webber, Davies & Cowie, 2011 ²⁶	No	NA	Yes	NA	NA	Yes	Yes	Yes	Yes	Yes
Empirical studies with clinicians	1	2	3	4	5	6	7	8	9	10
Fitch, McAndrew et al., 2013 ⁴⁰	No	NA	NA	NA	NA	Yes	Yes	Yes	Yes	Yes
Shin, Kim et al., 2018 ⁴¹	Yes	No	No	Yes	No	NA	NA	NA	NA	NA
Oostendorp, Rajapakse et al., 2019 ⁴	Yes	Yes	No	No	NA	Yes	Yes	Yes	Yes	Yes
Rustøen, Geerling et al., 2013a ³⁸	DK	No	No	DK	NA	Yes	Yes	Yes	Yes	Yes
Rustøen, Geerling et al., 2013b ³⁹	No	NA	NA	NA	NA	Yes	Yes	Yes	Yes	Yes
Wengström, Rundström et al., 2014 ¹¹	Yes	Yes	No	Yes	No	NA	NA	NA	NA	NA
Expert consensus studies	1	2	3	4	5	6	7	8	9	10
Alarcón, Estévez et al., 2019 ⁴⁴	No	NA	NA	NA	NA	Yes	Yes	Yes	Yes	NA
Boceta, De la Torre et al., 2016 ⁴⁵	Yes	Yes	Yes	Yes	No	Yes	Yes	No	DK	Yes
Camps Herrero, Torres et al., 2019 ⁴⁶	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Løhre, Klepstad et al., 2016 ⁴⁷	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Porta-Sales, Perez et al., 2016 ⁴⁸	Yes	Yes	Yes	No	Yes	NA	NA	NA	NA	NA

Note. DK: don't know; NA: not applicable. Numbered items are as follows:

1. Does the study include a definition of breakthrough pain endorsed by the authors and/or by participants? [If No/Don't know, proceed to Question 6. If Yes, continue].
2. Is the definition of breakthrough pain clear?
3. Do the authors/participants critique or evaluate the definition of breakthrough pain?
4. Is the definition of breakthrough pain newly proposed by the authors/participants [or is this a modification of an existing definition]?
5. If the definition of breakthrough pain is newly proposed, are the methods for its development clearly presented?
6. For studies with data on breakthrough pain characteristics/descriptions, is the sample experiencing breakthrough pain clearly described [Is it clear who the research is about]?
7. Is the population experiencing breakthrough pain appropriate?
8. Is it clear how the data on characteristics of breakthrough pain were attained?
9. Were the methods for attaining data on characteristics of breakthrough pain appropriate?
10. Were the data on characteristics of breakthrough pain clearly described?

questions were based on guidance from Nasa and colleagues.²⁰ An initial draft of the bespoke tool was piloted by KG, DES, and CL with four studies (two empirical studies and two DELPHI studies). This was subsequently refined to ensure clarity of items and finalised for use in the present review.

Results

Sixty-five eligible studies were included (Table 1). No studies were found with data from caregivers and only one study involved children with breakthrough pain.²¹ Figure 1 displays the flow diagram of search results. Inter-coder agreement between KG and DES for

exclusion/inclusion decisions by article title and abstract was substantial (0.73 Cohen's kappa coefficient). After discussion, KG and DES reached 100% agreement on all inclusion/exclusion decisions. Studies varied in quality, and for most both strengths and limitations were noted. For example, where applicable all studies clearly described an appropriate sample of patients experiencing breakthrough pain, and clearly described data on characteristics of breakthrough pain. However, a common limitation found with most studies was that the authors endorsed a breakthrough pain definition without critique or evaluation. Furthermore, of the 13 studies providing a newly proposed definition of breakthrough pain, only three presented




Figure 1. Flow of records for inclusion in a rapid systematic review of the definition, description, and classification of breakthrough pain by patients, caregivers, clinicians, and experts.

methods for its development clearly. Complete quality appraisals for each individual study are displayed in Table 1. Data extraction tables are available in Supplementary File 2. A schematic representation of the key breakthrough pain terms found is provided in Figure 2.

Empirical studies with patients. Thirty articles involved empirical studies with patients. Participants were adults with cancer ($n = 26$), adults or children receiving hospice care for cancer or other conditions ($n = 1$),²¹ adults with chronic pain due to cancer or other conditions ($n = 2$),^{9,22} and adults with chronic lower back pain ($n = 1$).²³ These were quantitative survey studies ($n = 26$) and qualitative interview studies ($n = 3$).^{24–26} Only one study asked patients their views on the meaning of breakthrough pain.²⁶ The term was not widely understood and some participants found it difficult to distinguish between background pain and breakthrough pain. Inclusion criteria for patients with breakthrough pain in each study are shown in Supplementary File 4. This was not clearly stated in eight studies.^{23,25,27–32} One²² cited Portenoy & Hagen's 1990 definition of breakthrough pain³³ as the inclusion criteria while five^{24,26,34–36} used the diagnostic algorithm developed by a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland.⁷ The criteria for breakthrough pain in one study³⁷ were pain rated as $\geq 5/$

10 on a visual analogue scale. The criteria for the remaining studies required patients to have both background pain (usually 'controlled') and transient peaks of more severe pain.

Empirical studies with clinicians. Six articles detailed four empirical studies with clinicians (three from the same study).^{11,38,39} Five were quantitative surveys with nurses^{11,38–40} or physicians⁴¹ about breakthrough pain in cancer. One was a study exploring the feasibility of generating reliable information on breakthrough pain in children with life-limiting conditions from narrative clinical records.⁴

In one study, 210 oncology nurses were given statements and asked to select which most accurately defined breakthrough pain. Most selected 'episodic pain that breaks through the stable background pain' and 'pain that requires additional or adjustments to current pain medication'.⁴⁰ A study with 1241 oncology nurses¹¹ used similar methods and reported that 72.5% selected the definition 'episodic pain that breaks through the stable background pain', 42.2% chose 'spontaneous pain/unpredictable incident', 22.5% chose 'predictable incident pain', 4.2% reported 'not sure', and 3.5% reported 'none of the above' (some respondents selected more than one response). A study with 92 palliative care doctors⁴¹ also asked participants to select between one of two breakthrough pain definitions. Most (66.3%) defined breakthrough pain as




Figure 2. Schematic representation of the key terms found in a rapid systematic review of experts', clinicians', and patients' definitions of breakthrough pain. Coloured boxes with bold outlines indicate the most commonly used terms. White boxes indicate descriptions used only by a minority in the literature. Boxes with dashed outlines signify suggestions from experts for terms to replace 'breakthrough pain'.

transient and exacerbating pain after control of background pain while 33.7% believed it was pain that occurred regardless of background pain.

In a feasibility study,⁴ the authors endorsed the World Health Organization's⁴² definition of breakthrough pain as 'a temporary increase in the severity of pain over and above the pre-existing baseline pain level'. Although a breakthrough pain data extraction instrument was developed, a pilot test showed poor agreement between raters when using it and there was no consensus on the terminology or definition of breakthrough pain to be used when reviewing paediatric narrative clinical records.

Expert group consensus studies. There were five expert group consensus studies, all using a 2-round Delphi method.⁴³ The experts involved were 64 pain specialists from pain units, palliative care, oncology, and geriatric medicine;⁴⁴ 90 cancer pain experts from pain units, palliative/home care, and oncology;⁴⁵ 69 oncology experts;⁴⁶ 24 authors who had published three or more articles on breakthrough pain in cancer in the past 10 years;⁴⁷ and 76 cancer pain experts from pain units, palliative care, and oncology. Only one study, which was focused on breakthrough pain in older adults,⁴⁴ stated whether experts specialised in adults or paediatrics. The aim of the studies was to reach a consensus on the definition,^{45,47,48} diagnosis,^{45,48} and/or management^{44-46,48} of breakthrough pain in adults with cancer.

One study did not endorse a breakthrough pain definition.⁴⁴ One⁴⁸ reported that experts endorsed the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland⁷ definition of breakthrough pain as a transient exacerbation of pain that occurs either spontaneously or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain. The experts believed that background pain controlled with around-the-clock (ATC) analgesics was a necessary diagnostic criterion for breakthrough pain. Experts in a more recent Delphi study⁴⁶ endorsed a similar definition of breakthrough pain as an 'acute exacerbation of high intensity pain of short duration and rapid onset, suffered by a patient whose baseline pain is stabilised and controlled by opioids'.

Most experts in a 2016 Delphi study⁴⁵ endorsed the definition of breakthrough pain as 'the occurrence of spontaneous or incidental exacerbations of pain' on a background of controlled baseline pain though only 50% believed that patients must be taking regular analgesics to achieve this. Experts in this study did not believe that end-of-dose failure was a subtype of breakthrough pain and end-of-dose failure was not mentioned in the remaining Delphi studies.

In contrast to the other Delphi studies, the majority of the European Association for Palliative Care Research Network⁴⁷ reported that transient cancer pain exacerbation was possible without controlled background pain or without significant background pain at all. Thus, the network proposed that the term 'episodic pain' could be used as an overarching concept for all significant transient cancer pain exacerbations.

Narrative expert reviews. There were 24 expert narrative reviews concerning adult cancer patients ($n = 5$), patients with cancer (without specifying ages; $n = 13$), and patients with cancer or non-malignant conditions ($n = 2$). Four reviews did not state the population. Data on breakthrough pain definitions and descriptions endorsed in expert narrative reviews are shown in [Supplementary File 5](#).

Breakthrough pain descriptions and classifications

Empirical studies with patients

Location Across studies, patients indicated that they most commonly experienced breakthrough pain in their back.^{9,21-23,36,49} Other locations included head/face/mouth,^{9,21,22} abdomen,^{21,22,24,25,36} leg(s),^{9,21-23,25} arm(s),^{9,21,22} neck/shoulder(s),^{9,21,22} glutes/hip(s) pelvis,^{21,23,25} rectum or anus,²¹ feet,²¹ and ribs/chest.^{22,25}

Severity In most studies, severity was rated on a 0-10 numerical rating scale. Most patients rated their pain as 7-8/10.^{21,23,27,28,30,31,37,49-52} In three studies, the average pain intensity for most patients was <7/10 (4-6/10,⁵¹ 5.9/10⁹ and 6/10⁵³). Average pain intensity was 8.5/10 in one study.³⁶ When patients were asked to rate whether their breakthrough pain was mild, moderate, or severe, the vast majority rated this as severe.^{22,33-35,54-56} In qualitative studies,^{25,26} patients described their pain as 'severe', 'excruciating', and one described difficulties rating their pain on a numerical rating scale.²⁶

Quality The most common breakthrough pain descriptors were sharp, burning, and stabbing.^{21,27,32,36,49} Other descriptions included pressure/squeezing/tight,^{21,49} aching,^{21,49} radiating/shooting,^{21,49} crampy,^{21,49} throbbing,^{21,25,49} penetrating,³⁰ heavy,^{30,36} splitting,³⁶ spasm,⁴⁹ squeezing,⁴⁹ crushing,²⁵ and pressing.⁴⁹ One patient stated that breakthrough pain feels like 'pulling, like my nerves are being stretched' (p.55525). Some patients used more emotional terms such as exhausting,³⁰ punishing-cruel, and fearful.³⁶

Temporality The most common average number of breakthrough pain episodes/day was 2–3.^{21,36,49,51,52} However, patients in other studies reported on average 1.3,⁵⁵ 2,^{9,50} 3,^{34,35} 3–4,^{22,28} 4,^{29,33,53} 4–5,⁵⁷ 5,⁵⁴ or 6⁵⁶ episodes/day. Episodes typically lasted between 11 and 60 min though many patients experienced episodes of shorter or longer duration.^{23,36,37,51,52,56} Average episode lengths included 30,^{33,49} 32.1,⁵⁴ 40.6,²² 45,⁹ 47.5,⁵⁷ 52,²¹ 60,^{34,35} and 81.2 min⁵⁵ The average time to peak intensity ranged from <5 to 30 min³⁷ (including 1–2,⁵⁵ within 3,³³ 10^{9,34} or up to 10 min,⁵⁰ and 15 min)^{35,49} but was most commonly 5–10 min^{36,52,57} When asked to describe onset, more patients stated that their breakthrough pain had a gradual than a sudden onset in three studies^{25,28,56} while the reverse was found in one other study.²²

Subtypes In seven reviews,^{21,22,34–37,49} patients' breakthrough pain was described as incident, spontaneous, or a combination, of which incident breakthrough pain was the most common followed by spontaneous. Authors of three reviews^{28,29,58} included a third subtype; end-of-dose failure, which typically only occurred in a minority of patients. In three studies, incident breakthrough pain was subclassified into predictable, unpredictable, or a combination, with the majority being unpredictable.^{22,49,57} Four studies classified incident breakthrough pain (from most to least common) into volitional, non-volitional, a combination, and procedural.^{34–37} Patients' breakthrough pain was classified into nociceptive (somatic or visceral), neuropathic, or a combination in eight studies,^{22,23,33,36,50,51,56} of which nociceptive or a combination was the most common.

Exacerbating factors Patients cited the following exacerbating factors: movement/walking,^{25,27,33,36,49,54,56} standing,^{27,36,59} lying down,^{25,36,52} sitting,^{25,36,52,59} household/everyday activities,^{27,49,57} eating,^{24,52,57,59} bodily movements (e.g. swallowing, urination, and defecation),^{54,57} non-volitional activities such as coughing,^{25,28,33,36,54,56} touch,⁵⁴ stress/anxiety,^{54,59} cold/the weather,⁵⁹ treatment side-effects,^{24,28,54} the disease process,^{28,52,59} or an unidentifiable reason.^{8,27,28,54,59} The most commonly cited of these were walking/movement, coughing, and no identifiable reason.

Impact of breakthrough pain Most patients reported breakthrough pain stopped them doing things and interfered with every aspect of life.^{32,34,35} Patients reported moderate-high interference in everyday life from

breakthrough pain (when a 0–10 scale was used to measure this, the mean score was 5–10/10) for general activity,^{9,27,35,36,49,59,60} walking,^{9,27,35,36,49,59,60} work,^{8,9,27,36,49,59,60} relationships,^{8,9,27,36,49,59,60} sleep,^{8,9,27,36,49,59,60} mood,^{8,27,35,36,59,60} and enjoyment of life.^{8,9,27,35,36,49,59,60} Physical functioning was significantly worse for patients with breakthrough pain versus without breakthrough pain⁵⁹ and was worse in breakthrough pain patients with more frequent and/or longer lasting episodes.⁵¹ Patients with breakthrough pain also reported higher levels of anxiety^{9,49,59} and depression^{9,59} and worse mental wellbeing^{32,49} and quality of life²² compared to those without breakthrough pain. In qualitative studies, patients reported having to change their lifestyle and limit their movement to reduce the pain.^{24–26} They described feeling sad, depressed, hopeless, helpless, and even suicidal.^{24–26} In one study, patients reported a lack of control over their body.²⁶

Empirical studies with clinicians. No empirical studies with clinicians included data on breakthrough pain location, subtypes, or classifications. Nurses in two studies estimated breakthrough pain severity as moderate-severe (7 or 8/10⁴⁰) or as not severe (0.1%), mild (0.6%), moderate (19.5%), or severe (75.5%).³⁸ The quality of breakthrough pain was described by clinicians in one study as 'increased pressure in head', pins and needles, achiness, headache, cramps, spasms, or stiffness.⁴

Half of nurses in one study estimated that breakthrough pain occurred at least twice a day, 13% estimated one episode or less per day and 37% were unsure. The majority estimated time to peak intensity of 11–20 min with episodes lasting 31–60 min but many unsure.⁴⁰ Another study with nurses reported that they had patients who experienced breakthrough pain less than once a day (9%), once a day (13.9%), 2–3 times a day (46.6%), or >3 times a day (16.4%); 14.1% did not know.³⁸ Clinicians in a study that involved generating information from paediatric narrative clinical records noted that pain might be breakthrough pain if it has a rapid onset.⁴

Exacerbating factors noted in one study by nurses included movement, the existing condition, treatment, and eating,³⁸ Data on interference due to breakthrough pain was present in the two studies with nurse participants. Nurses reported breakthrough pain caused some (55.2%) or complete (43.6%) interference with patients' everyday activities⁴⁰ and that it specifically interfered with patients' enjoyment of life, work, mood, sleep, movement, general activity, and relationships.³⁸ In both studies with nurse participants, breakthrough

pain was viewed as having a significant impact on quality of life.^{38,40} Clinicians in the only paediatric study felt that descriptors that could indicate breakthrough pain included ‘disturbed sleep’, ‘unsettled’, ‘irritation’, and ‘distress’.⁴

Expert group consensus studies. Breakthrough pain location, quality, subtypes, exacerbating factors, interference, and psychological issues were not mentioned in the expert group consensus studies. One consensus study⁴⁵ specified the level of pain severity ($\geq 7/10$ on a 0–10 rating scale) for pain to be diagnosed as breakthrough pain. In another study,⁴⁷ experts agreed that breakthrough pain intensity must be more than two points higher than background pain on a 0–10 rating scale but did not agree that breakthrough pain can best be assessed by an increase in pain score to a predefined number.

Statements on the frequency of breakthrough pain episodes were rated in only one study.⁴⁶ Consensus was not reached regarding whether breakthrough pain diagnosis requires >4 episodes/day, though experts’ comments suggested that they did not agree with establishing a minimum number of episodes since a single episode could be diagnosed as breakthrough pain. Experts in one study⁴⁵ agreed that breakthrough pain episodes last <60 min. Episode length was not discussed in the remaining studies.

Discussion

This rapid systematic review aimed to update and expand upon Haugen and colleagues¹² review of cancer breakthrough pain assessment and classification. We identified 65 highly heterogeneous studies of varying quality that included data on breakthrough pain definitions, descriptions, and classifications reported by patients ($n = 30$), clinicians ($n = 6$), and experts ($n = 29$). These were five expert group consensus studies, 24 expert narrative reviews, and 37 empirical studies.

In only one study²⁶ were patients asked about their views on the meaning of breakthrough pain, the term was poorly understood and they found it hard to distinguish breakthrough pain from background pain. In eight studies, the definition of breakthrough pain used as patient inclusion criteria was not operationally defined.

In empirical studies with clinicians, most endorsed the broad definition of breakthrough pain as a severe, rapid-onset, and short-lived pain occurring in patients with controlled mild-moderate background pain. However, results showed that a lack of knowledge and confidence in defining breakthrough pain was common in oncology nurses and palliative care doctors. There

was also poor consensus in identifying breakthrough pain in paediatric clinical records by clinicians.⁴

Across studies, experts typically endorsed the broad definition of breakthrough pain above. Breakthrough pain can be incident, spontaneous, predictable, or unpredictable and may be the same pain as background pain, or different. Exceptions to this definition included two expert narrative reviews proposing that breakthrough pain could be only moderate-severe^{61,62} and one suggesting that breakthrough pain could occur in patients with treated or untreated background pain.⁶³ Significantly, the European Association for Palliative Care Research Network⁴⁷ proposed that breakthrough pain could occur without any background pain and thus the term ‘episodic pain’ should be used instead to cover all significant transient cancer pain exacerbations. The EAPC Research Network⁶⁴ also suggested ‘episodic pain’ should replace ‘breakthrough pain’, while an expert review proposed the term ‘incident pain’ should be used instead.⁶⁵ However, these changes have been debated^{66,67} and not yet been implemented in the literature.

Breakthrough pain descriptions and characteristics were broadly in alignment across studies though temporal features varied widely. For example, the average length of a breakthrough pain episode was stated as ranging between <5 min to ‘many hours’ by experts, while the average length stated by patients ranged from 11 to >80 min. Similarly, the average number of episodes per day ranged from 1 to 7.44 (experts) and 1–6 (patients) with some experts stating that >4 episodes/day indicated poorly controlled background pain rather than breakthrough pain. Many patients with chronic cancer or noncancer pain on ATC opioids experience end-of-dose pain and an enduring debate in the literature is whether end-of-dose failure is actually a type of BTP. However, few studies mention end-of-dose pain explicitly and a systematic review to examine how the frequency of end-of-dose pain is linked to the formulations of long-acting opioids had to use ‘breakthrough pain’ as a surrogate parameter.⁶⁸

As this was a rapid systematic review, study quality assessment focused only on the review’s primary objectives, using a bespoke study quality assessment based on previous tools.^{18–20} Quality assessment outcomes may be different if a more in-depth assessment tool was used. While the current review did not aim to identify BTP assessment tools, we conducted an extensive systematic review of BTP assessment tools in 2021.^{13,14} The current review expanded on Haugen and colleagues’ work by including all types of BTP, not just cancer-related BTP. Moreover, 30 of the 65 included studies in the current review were published after the

first BTP review, indicating the growth of this field and the need for an updated review.

Thirteen years after Haugen and colleagues review,¹² it is striking that a very similar range of overlapping but different breakthrough pain definitions were found, with no single broadly accepted definition. This is despite proposals for a universal definition from expert groups including the European Association for Palliative Care Research Network.⁴⁷ Breakthrough pain is a significant problem for the majority of patients with cancer and those at end-of-life.^{1,2} As findings from this review demonstrate, it has a profound impact on patients' functioning, mental, and physical wellbeing. However, clinicians demonstrate a lack of confidence in defining breakthrough pain, which likely leads to underdiagnosis and undermanagement. Minor variations to the definition and a reluctance to endorse one definition in the literature perpetuate these problems.

The current review found no studies asking caregivers on their views on breakthrough pain, and only one that included paediatric patients. There is a need for more research on paediatric breakthrough pain since it is not clear if or how breakthrough pain may differ in children versus adults. Evidence suggests it is common in children with life-limiting conditions, including cancer, and at end-of-life.^{4,6} Moreover, children and their families report that breakthrough pain is a major concern, often describing it as 'intolerable' or 'out of control'.⁶⁹

A compromise on breakthrough pain nomenclature achieved via appropriate methodology is needed to reach a consensus, defined in this context as the position generally agreed upon at a given time by most scientists specialised in a given field, based on their interpretation of the available evidence.⁷⁰ There are three best known consensus methods that try to push a field towards consensus on important clinical issues, that is, the Delphi process, the nominal group technique (also known as the expert panel), and the consensus development conference. In the case of breakthrough pain, despite the fact that some of these methods have been employed, as our systematic review clearly demonstrates, no consensus has been achieved and researchers and clinicians continue to endorse different definitions in their everyday clinical practice, research, and writing.⁷⁰ The current review showed a minimum level of agreement on the definition in the literature that aligns closely with the definition of breakthrough pain as 'a temporary increase in the severity of pain over and above the pre-existing baseline pain level'.⁴² A universal working definition would allow for the collection of reliable incidence and prevalence data, inform the development and validation of breakthrough pain assessment tools for different patient populations, allow for further refinement of the

construct if needed and ultimately, and improve breakthrough pain diagnosis and management. To summarise, the present systematic review is a small first step towards achieving eventual consensus in a definition of breakthrough pain by demonstrating the magnitude of the problem and providing a comprehensive and exhaustive summary of different definitions. Future research such as BEACON is now needed involving all key stakeholders, that is, patients, caregivers, clinicians, and researchers, in order to achieve a universal working definition.

Author contributions

CL conceived the idea; KG, DES, and CL planned and designed the study protocol, search strategy, data extraction and quality assessment, and wrote the first draft; RH, SB, CM, DR, EH, KR, A-K A, BC, and MJ provided critical insights. All authors have approved and contributed to the final written manuscript.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Great Ormond Street Children's Charity (grant number: V5118 and V4421).

ORCID iDs

Richard Hain  <https://orcid.org/0000-0001-5838-1713>

Christina Liossi  <https://orcid.org/0000-0003-0627-6377>

Supplemental Material

The Supplementary Material for this article is available online.

References

1. Steindal SA, Bredal IS, Sørbye LW, et al. Pain control at the end of life: a comparative study of hospitalized cancer and noncancer patients. *Scand J Caring Sci* 2011; 25: 771–779.
2. Mercadante S. Breakthrough pain in cancer patients: prevalence, mechanisms and treatment options. *Curr Opin Anaesthesiol* 2015; 28: 559–564. DOI: [10.1097/ACO.0000000000000224](https://doi.org/10.1097/ACO.0000000000000224)
3. Deandrea S, Corli O, Consonni D, et al. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. *J Pain Symptom Manage* 2014; 47: 57–76. DOI: [10.1016/j.jpainsymman.2013.02.015](https://doi.org/10.1016/j.jpainsymman.2013.02.015)

4. Oostendorp LJ, Rajapakse D, Kelly P, et al. Documentation of breakthrough pain in narrative clinical records of children with life-limiting conditions: feasibility of a retrospective review. *J Child Health Care* 2019; 23: 564–578. DOI: [10.1177/1367493518807312](https://doi.org/10.1177/1367493518807312)
5. Friedrichsdorf SJ, Finney D, Bergin M, et al. Breakthrough pain in children with cancer. *J Pain Symptom Manage* 2007; 34: 209–216.
6. Friedrichsdorf SJ and Postier A. Management of breakthrough pain in children with cancer. *J Pain Res* 2014; 7: 117–123. DOI: [10.2147/JPR.S58862](https://doi.org/10.2147/JPR.S58862)
7. Davies AN, Dickman A, Reid C, Science Committee of the Association for Palliative Medicine of Great Britain and Ireland, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. *Eur J Pain* 2009; 13: 331–338. DOI: [10.1016/j.ejpain.2008.06.014](https://doi.org/10.1016/j.ejpain.2008.06.014)
8. Burton B and Zeppetella G. Assessing the impact of breakthrough cancer pain. *Br J Nurs* 2011; 20: S16–S19.
9. Narayana A, Katz N, Shillington AC, et al. National Breakthrough Pain Study: prevalence, characteristics, and associations with health outcomes. *Pain* 2015; 156: 252–259. DOI: [10.1097/01.j.pain.0000460305.41078.7d](https://doi.org/10.1097/01.j.pain.0000460305.41078.7d)
10. Webber K, Davies AN, Zeppetella G, et al. Development and validation of the breakthrough pain assessment tool (BAT) in cancer patients. *J Pain Symptom Manage* 2014; 48: 619–631.
11. Wengstrom Y, Rundstrom C, Geerling J, et al. The management of breakthrough cancer pain—educational needs a European nursing survey. *Eur J Cancer Care* 2014; 23: 121–128. DOI: [10.1111/ecc.12118](https://doi.org/10.1111/ecc.12118)
12. Haugen DF, Hjermstad MJ, Hagen N, European Palliative Care Research Collaborative EPCRC, et al. Assessment and classification of cancer breakthrough pain: a systematic literature review. *Pain* 2010; 149: 476–482. DOI: [10.1016/j.pain.2010.02.035](https://doi.org/10.1016/j.pain.2010.02.035)
13. Lioffi C, Greenfield K, Schoth DE, et al. A systematic review of measures of breakthrough pain and their psychometric properties. *J Pain Symptom Manage* 2021; 62: 1041–1064. DOI: [10.1016/j.jpainsymman.2021.04.018](https://doi.org/10.1016/j.jpainsymman.2021.04.018)
14. Greenfield K, Holley S, Schoth DE, et al. A protocol for a systematic review and meta-analysis to identify measures of breakthrough pain and evaluate their psychometric properties. *BMJ Open* 2020; 10: e035541.
15. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Syst Rev* 2021; 74: 790–799.
16. Garritty C, Gartlehner G, Nussbaumer-Streit B, et al. Cochrane rapid reviews methods group offers evidence-informed guidance to conduct rapid reviews. *J Clin Epidemiol* 2020; 130: 13–22.
17. Greenfield K, Lioffi C and Schoth DE. Definition, description and classification of breakthrough pain by patients, their caregivers, healthcare professionals and experts: a systematic literature review. *PROSPERO* 2022: CRD42022340458.
18. Collaboration CcsHMC-E. *LEGEND evidence appraisal of a single study* <https://www.cincinnatichildrens.org/research/divisions/janderson-center/evidence-based-care/legend> (2012, accessed 12 June 2022).
19. Downes MJ, Brennan ML, Williams HC, et al. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). *BMJ Open* 2016; 6: e011458.
20. Nasa P, Jain R and Juneja D. Delphi methodology in healthcare research: how to decide its appropriateness. *World J Methodol* 2021; 11: 116–129.
21. Fine PG and Busch MA. Characterization of breakthrough pain by hospice patients and their caregivers. *J Pain Symptom Manage* 1998; 16: 179–183.
22. Madariaga Munoz MC, Villegas Estevez F, Jimenez Lopez AJ, et al. Evaluation of quality of life and satisfaction of patients with neuropathic pain and breakthrough pain: economic impact based on quality of life. *Pain Res Treat* 2018; 2018: 5394021. DOI: [10.1155/2018/5394021](https://doi.org/10.1155/2018/5394021)
23. Torres LM, Jimenez AJ, Cabezon A, et al. Prevalence and characterization of breakthrough pain associated with chronic low back pain in the South of Spain: a cross-sectional, multicenter, observational study. *Pain Res Treat* 2018; 2018: 4325271. DOI: [10.1155/2018/4325271](https://doi.org/10.1155/2018/4325271)
24. Liu Q, Gao LL, Dai YL, et al. Breakthrough pain: a qualitative study of patients with advanced cancer in Northwest China. *Pain Manag Nurs* 2018; 19: 506–515. DOI: [10.1016/j.pmn.2017.11.006](https://doi.org/10.1016/j.pmn.2017.11.006)
25. Pathmawathi S, Beng TS, Li LM, et al. Satisfaction with and perception of pain management among palliative patients with breakthrough pain: a qualitative study. *Pain Manag Nurs* 2015; 16: 552–560. DOI: [10.1016/j.pmn.2014.10.002](https://doi.org/10.1016/j.pmn.2014.10.002)
26. Webber K, Davies AN and Cowie MR. Breakthrough pain: a qualitative study involving patients with advanced cancer. *Support Care Cancer* 2011; 19: 2041–2046. DOI: [10.1007/s00520-010-1062-z](https://doi.org/10.1007/s00520-010-1062-z)
27. Bedard G, Hawley P, Zhang L, et al. A survey of Canadian cancer patients' perspectives on the characteristics and treatment of breakthrough pain. *Support Care Cancer* 2013; 21: 2557–2563. DOI: [10.1007/s00520-013-1817-4](https://doi.org/10.1007/s00520-013-1817-4)
28. Bhatnagar S, Upadhyay S and Mishra S. Prevalence and characteristics of breakthrough pain in patients with head and neck cancer: a cross-sectional study. *J Palliat Med* 2010; 13: 291–295. DOI: [10.1089/jpm.2009.0266](https://doi.org/10.1089/jpm.2009.0266)

29. Lasheen W, Walsh D, Sarhill N, et al. Intermittent cancer pain: clinical importance and an updated cancer pain classification. *Am J Hosp Palliat Care* 2010; 27: 182–186. DOI: [10.1177/1049909109350206](https://doi.org/10.1177/1049909109350206)
30. Hansen RB, Frost CØ, Sonne NM, et al. Exploring the patients' perception of background and breakthrough pain: a McGill Pain Questionnaire inquiry in patients with bone cancer pain. *J Palliat Med* 2019; 22: 881–883. DOI: [10.1089/jpm.2018.0621](https://doi.org/10.1089/jpm.2018.0621)
31. Mercadante S, Adile C, Torta R, et al. Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients. *Curr Med Res Opin* 2013; 29: 93–97. DOI: [10.1185/03007995.2012.755120](https://doi.org/10.1185/03007995.2012.755120)
32. O'Hagan P, Mercadante S and O'Hagan P. Breakthrough cancer pain: the importance of the right treatment at the right time. *Eur J Pain* 2018; 22: 1362–1374. DOI: [10.1002/ejp.1225](https://doi.org/10.1002/ejp.1225)
33. Portenoy RK and Hagen NA. Breakthrough pain: definition, prevalence and characteristics. *Pain* 1990; 41: 273–281. DOI: [10.1016/0304-3959\(90\)90004-W](https://doi.org/10.1016/0304-3959(90)90004-W)
34. Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. *J Pain Symptom Manage* 2013; 46: 619–628. DOI: [10.1016/j.jpainsymman.2012.12.009](https://doi.org/10.1016/j.jpainsymman.2012.12.009)
35. Davies A, Zeppetella G, Andersen S, et al. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. *Eur J Pain* 2011; 15: 756–763. DOI: [10.1016/j.ejpain.2010.12.004](https://doi.org/10.1016/j.ejpain.2010.12.004)
36. Perez-Hernandez C, Blasco A, Gandara A, et al. Prevalence and characterization of breakthrough pain in patients with cancer in Spain: the CARPE-DIO study. *Sci Re* 2019; 9: 17701, DOI: [10.1038/s41598-019-54195-x](https://doi.org/10.1038/s41598-019-54195-x)
37. Ferrero VT, Oset MM, Masferrer JP, PrevaDIOR Study Group, et al.. Prevalence and characterization of breakthrough pain in cancer patients with proctalgia treated with 3D pelvic radiotherapy. *Clin Transl Oncol* 2019; 21: 1707–1711. DOI: [10.1007/s12094-019-02102-1](https://doi.org/10.1007/s12094-019-02102-1)
38. Rustoen T, Geerling JI, Pappa T, et al. A European survey of oncology nurse breakthrough cancer pain practices. *Eur J Oncol Nurs* 2013; 17: 95–100. DOI: [10.1016/j.ejon.2012.05.005](https://doi.org/10.1016/j.ejon.2012.05.005)
39. Rustoen T, Geerling JI, Pappa T, et al. How nurses assess breakthrough cancer pain, and the impact of this pain on patients' daily lives - results of a European survey. *Eur J Oncol Nurs* 2013; 17: 402–407. DOI: [10.1016/j.ejon.2012.12.002](https://doi.org/10.1016/j.ejon.2012.12.002)
40. Fitch MI, McAndrew A and Burlein-Hall S. A Canadian online survey of oncology nurses' perspectives on the defining characteristics and assessment of breakthrough pain in cancer. *Can Oncol Nurs J* 2013; 23: 85–99.
41. Shin J, Kim DY, Lee J, et al. Practice patterns in distinguishing between background pain and breakthrough pain during patient education: a Korean physician survey. *J Cancer Educ* 2018; 33: 284–292. DOI: [10.1007/s13187-016-1113-3](https://doi.org/10.1007/s13187-016-1113-3)
42. World Health Organization. *WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses*. World Health Organization, 2012.
43. Linstone HA and Turoff M. *The delphi method*. 1st ed. Boston: Addison-Wesley, 1975.
44. Alarcon MDL, Estevez FV, Cabezon-Gutierrez L, et al. Expert consensus on the management of breakthrough cancer pain in older patients. A Delphi study. *J Geriatr Oncol* 2019; 10: 643–652. DOI: [10.1016/j.jgo.2019.03.012](https://doi.org/10.1016/j.jgo.2019.03.012)
45. Boceta J, De la Torre A, Samper D, et al. Consensus and controversies in the definition, assessment, treatment and monitoring of BTcP: results of a Delphi study. *Clin Transl Oncol* 2016; 18: 1088–1097.
46. Camps-Herrero C, Antón Torres A, Cruz-Hernandez JJ, et al. Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts. *J Pain Res* 2019; 12: 2349–2358. DOI: [10.2147/JPR.S203903](https://doi.org/10.2147/JPR.S203903)
47. Lohre ET, Klepstad P, Bennett MI, European Association for Palliative Care Research Network, et al.. From “breakthrough” to “episodic” cancer pain? A European Association for Palliative Care research network expert delphi survey toward a common terminology and classification of transient cancer pain exacerbations. *J Pain Symptom Manage* 2016; 51: 1013–1019. DOI: [10.1016/j.jpainsymman.2015.12.329](https://doi.org/10.1016/j.jpainsymman.2015.12.329)
48. Porta-Sales J, Perez C, Escobar Y, et al. Diagnosis and management of breakthrough cancer pain: have all the questions been resolved? A Delphi-based consensus assessment (DOIRON). *Clin Transl Oncol* 2016; 18: 945–954. DOI: [10.1007/s12094-015-1468-7](https://doi.org/10.1007/s12094-015-1468-7)
49. Katz NP, Gajria KL, Shillington AC, et al. Impact of breakthrough pain on community-dwelling cancer patients: results from the National Breakthrough Pain Study. *Postgrad Med* 2017; 129: 32–39. DOI: [10.1080/00325481.2017.1261606](https://doi.org/10.1080/00325481.2017.1261606)
50. Cascella M, Crispo A, Esposito G, et al. Multidimensional statistical technique for interpreting the spontaneous breakthrough cancer pain phenomenon: a secondary analysis from the IOPS-MS Study. *Cancers* 2021; 13: 4018. DOI: [10.3390/cancers13164018](https://doi.org/10.3390/cancers13164018)
51. Kang JH, Koh S-J, Oh SY, et al. Interference with daily functioning by breakthrough pain in patients with cancer. *Support Care Cancer* 2020; 28: 5177–5183. DOI: [10.1007/s00520-020-05329-9](https://doi.org/10.1007/s00520-020-05329-9)
52. Mercadante S, Adile C, Giarratano A, et al. Breakthrough pain in patients with abdominal cancer pain. *Clin J Pain* 2014; 30: 510–514, DOI: [10.1097/AJP.0000000000000004](https://doi.org/10.1097/AJP.0000000000000004)
53. Fan R, Li X, Yang S, et al. Retrospective observational study on the characteristics of pain and associated factors of breakthrough pain in advanced cancer patients. *Pain*

- Res Manag* 2022; 2022: 8943292. DOI: [10.1155/2022/8943292](https://doi.org/10.1155/2022/8943292)
54. Petzke F, Radbruch L, Zech D, et al. Temporal presentation of chronic cancer pain: transitory pains on admission to a multidisciplinary pain clinic. *J Pain Symptom Manage* 1999; 17: 391–401.
 55. Portenoy RK, Bruns D, Shoemaker B, et al. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics. *J Opioid Manag* 2010; 6: 97–108.
 56. Portenoy RK and Hagen NA. Breakthrough pain: definition and management. *Oncology* 1989; 3: 25–29.
 57. Mercadante S, Maltoni M, Russo D, et al. The prevalence and characteristics of breakthrough cancer pain in patients receiving low doses of opioids for background pain. *Cancers* 2021; 13: 1058. DOI: [10.3390/cancers13051058](https://doi.org/10.3390/cancers13051058)
 58. Gutsell T, Walsh D, Zhukovsky DS, et al. A prospective study of the pathophysiology and clinical characteristics of pain in a palliative medicine population. *Am J Hosp Palliat Care* 2003; 20: 140–148.
 59. Portenoy RK, Bruns D, Shoemaker B, et al. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 2: impact on function, mood, and quality of life. *J Opioid Manag* 2010; 6: 109–116.
 60. Caraceni A, Martini C, Zecca E, Working Group of an IASP Task Force on Cancer Pain, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. *Palliat Med* 2004; 18: 177–183. DOI: [10.1191/0269216304pm890oa](https://doi.org/10.1191/0269216304pm890oa)
 61. Webster LR. Breakthrough pain in the management of chronic persistent pain syndromes. *Am J Manag Care* 2008; 14: S116–S122.
 62. Davies AN. Cancer-related breakthrough pain. *Br J Hosp Med* 2006; 67: 414–416.
 63. Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. *Eur J Pain* 2005; 9: 195–206.
 64. Mercadante S, Radbruch L, Caraceni A, Steering Committee of the European Association for Palliative Care EAPC Research Network, et al. Episodic (breakthrough) pain - consensus conference of an expert working group of the European Association for Palliative Care. *Cancer* 2002; 94: 832–839. DOI: [10.1002/cncr.10249](https://doi.org/10.1002/cncr.10249)
 65. McQuay HJ and Jadad AR. Incident pain. *Cancer Surv* 1994; 21: 17–24.
 66. Davies AN, Dickman A, Farquhar-Smith P, et al. Incorrect use of the English language term “episodic”. *J Pain Symptom Manage* 2016; 52: e1.
 67. Løhre ET, Klepstad P, Bennett MI, et al. Authors’ reply to Davies et al. *J Pain Symptom Manage* 2016; 52: e1–e2.
 68. Zimmermann M and Richarz U. End-of-dose pain in chronic pain: does it vary with the use of different long-acting opioids? *Pain Pract* 2014; 14: 757–769.
 69. Namisango E, Bristowe K, Allsop MJ, et al. Symptoms and concerns among children and young people with life-limiting and life-threatening conditions: a systematic review highlighting meaningful health outcomes. *Patient* 2019; 12: 15–55.
 70. Ordway D. *Covering scientific consensus: what to avoid and how to get it right*, 2021. (accessed 23 June 2023).